"There is an increasing
number of orphan drugs on the U.S. market that have price points of hundreds of
thousands dollar annually, and the industry has shifted its R&D focus to
such drugs — so the cost problem is cumulative, and the trend will be that the
overall affordability problem will exacerbate."
— Elan Rubinstein, Pharm.D., principal at EB Rubinstein
Associates, talked with AIS's RADAR
on Specialty Pharmacy about the impact pricey new gene therapies
and other orphan drugs have on payers.
No comments:
Post a Comment